Rhythm Pharmaceuticals stock price target raised to $95 by BofA on positive trial data

Rhythm Pharmaceuticals (RYTM) reported positive Phase 2 trial results for its oral obesity treatment, bivamelagon, showing a 9.31% BMI reduction in the high-dose cohort, comparable to its existing setmelanotide but offering the advantage of once-daily oral dosing. This led BofA Securities to raise its price target to $95, maintaining a Buy rating, aligning with a strong bullish consensus among analysts. The company plans to advance bivamelagon to Phase 3 trials, with formulation refinement expected by H1 2026, leveraging its high gross profit margins and extended patent protection through 2040.

Analysis

Rhythm Pharmaceuticals (RYTM) has significantly de-risked its pipeline with positive Phase 2 trial results for its oral obesity treatment, bivamelagon. The high-dose cohort demonstrated a 9.31% reduction in Body Mass Index (BMI), a figure that aligns with key opinion leader expectations and is comparable to the efficacy of the company's existing injectable treatment, setmelanotide. The primary strategic advantage for bivamelagon lies in its once-daily oral dosing, offering a substantial convenience improvement. This positive development has been met with strong bullish sentiment from analysts, evidenced by BofA Securities raising its price target to $95 from $73 and Stifel and Leerink Partners issuing Buy/Outperform ratings. The company's financial position is supported by robust gross profit margins of 89.62% and long-term value is underpinned by extended patent protection for bivamelagon through 2040. However, the path to commercialization has a clear timeline; management intends to complete formulation work to improve tolerability by the first half of 2026 before initiating Phase 3 trials, indicating a multi-year development runway. The stock's 16.36% year-to-date surge and high beta of 2.27 reflect both the market's optimism and inherent volatility.

Key Decisions for Investors

• Investors should view the positive Phase 2 data as a major de-risking event, as bivamelagon's comparable efficacy to setmelanotide combined with a superior oral delivery profile strengthens the company's long-term commercial prospects in rare genetic obesity.
• The timeline for initiating Phase 3 trials is a critical factor to monitor, as it is contingent on completing formulation work by the first half of 2026, creating a key milestone that will dictate the drug's path to market.
• Given the stock is trading near its 52-week high with a high beta of 2.27, prospective investors should weigh the significant potential upside against the inherent volatility and the multi-year development horizon before the drug can generate revenue.
• Consider the company's strong fundamentals, including an 89.62% gross profit margin and patent protection through 2040, as key components supporting the current $5.54 billion valuation.